P21, as a vital member of CDK inhibitor, suppresses cyclin B1/cdc2 complex activity by interacting with many important proteins, including cdc2 and GADD45A 44, thereby inhibiting the G2/M transition in various cancer types both p53-dependent and p53-independent 45, 46. Here, CDKN1A is linked to cancer.